RIMEGEPANT for Migraine

Inclusion criteria

• {"criterion_text":"-\tSigned Written Informed Consent Written informed consent must be obtained from the patient in accordance with requirements of the ethics committee, prior to the initiation of any protocol-required procedures."}
• {"criterion_text":"-\tTarget Population o Patients with a body mass index: ≥30 kg/m2 ; o Patient has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:  Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age  Migraine attacks, on average, lasting about 4 - 72 hours if untreated. Not more than 8 attacks of moderate or severe intensity per month within last 3 months  Patients must be able to distinguish migraine attacks from tension/cluster headaches.  Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit, which is maintained during the Screening Period.  Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit, which is maintained during the Screening Period.  Patients on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to study entry."}
• {"criterion_text":"-\tAge and Reproductive Status o Male and Female patients ≥ 18 years and older Women of childbearing potential (WOCBP) and non-sterile men must be using two acceptable methods of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. Males with vasectomy are considered surgically sterile provided the procedure occurred more than 6 months prior to study participation o No clinically significant abnormality identified on the medical or laboratory evaluation. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the investigator considers that the finding is not clinically significant and will not introduce additional risk factors and will not interfere with the study procedures o At the Baseline Visit prior to dispensing Investigational Study Medication, WOCBP must have a negative urine pregnancy test o Women must not be breastfeeding"}

Exclusion criteria

• {"criterion_text":"-\tDisease Target Exclusion Patient has a history of basilar migraine or hemiplegic migraine"}
• {"criterion_text":"-\tMedical History and Concurrent Diseases o Patient history of HIV disease o Patient history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS),Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening. o Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however patients can be included who have stable hypertension and/or diabetes for 3 months prior to being enrolled) o Patient has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator’s opinion, might interfere with study assessments o Patient has a history of gastric, or small intestinal surgery, or has a disease thatcauses malabsorption o The patient has a history or current evidence of any significant and/or unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known suspected infection, hepatitis B or C, or cancer) that, in the investigator’s opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial o History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or patients who have met DSM-V criteria for any significant substance use disorder within the past 12 months from the date of the screening o Patients should be excluded if they have a positive drug screen for drugs of abuse that in the investigator’s judgment is medically significant, in that it would impact the safety of the patient or the interpretation of the study results."}
• {"criterion_text":"-\tAllergies and Adverse Drug Reactions History of drug or other allergy which, in the opinion of the principal investigator, makes the subject unsuitable for participation in the study"}
• {"criterion_text":"-\tSex and Reproductive Status o Females of child-bearing potential who are unwilling or unable to use an acceptable contraceptive method or abstinence to avoid pregnancy for the entire study period and for 56 days after the study. o Women who are pregnant or breastfeeding. Women with a positive pregnancy test on enrollment or prior to study drug administration"}
• {"criterion_text":"-\tECG and Laboratory Test Findings o Estimated glomerular filtration rate (eGFR) ≤ 40 ml/min/1.73m2 o Corrected QT interval > 470 msec (QTc by method of Frederica), during theScreening/Baseline Phase o Left Bundle Branch block o Right Bundle Branch Block with a QRS duration ≥ 150 msec. o Intraventricular Conduction Defect with a QRS duration ≥ 150 msec. o Serum bilirubin (Total, Direct or Indirect) > 1,0 mg/dl o Neutrophil count ≤ 40 % o AST (SGOT) or ALT (SGPT) > 45 U/l"}

Primary endpoints

• {"endpoint_text":"-\tResponse or non-response to rimegepant 75 mg or 2x75 mg expressed as percentage in pain freedom or freedom from the most bothersome migraine-associated symptom apart from headache after 2 hours (reported in questionnaire)","definition_or_measurement_approach":"Percentage of patients achieving pain freedom or freedom from the most bothersome migraine-associated symptom (apart from headache) at 2 hours post-dose, as reported in a questionnaire."}

Secondary endpoints

• {"endpoint_text":"-\tFreedom from photophobia, phonophobia, nausea and pain relief 2 hours after administration of rimegepant in either 75 mg or 2x75 mg during a moderate to severe migraine episode; probability of using rescue medication within 24 hours after the dose; sustained freedom from pain, sustained pain relief, pain relapse 2 hours to 48 hours after the dose -\tBlood: sex steroid levels, rimegepant concentration, CGRP. parameters: Total body weight, total body water (TBW), free mass (FFM), fat mass (FM), s","definition_or_measurement_approach":"Assessment at 2 hours post-dose of freedom from photophobia, phonophobia, nausea and pain relief; probability of using rescue medication within 24 hours; sustained freedom/pain relief and pain relapse between 2 and 48 hours; blood measures including sex steroid levels, rimegepant concentration, CGRP; body composition parameters (total body weight, TBW, FFM, FM)."}

Austria

Earliest CTIS Part Ii Submission Date

05-03-2026

Latest Decision Or Authorization Date

13-03-2026

Processing Time Days

8

Number Of Sites

1

Number Of Participants

26

Primary sponsor

Full Name

Konvent Der Barmherzigen Brueder

Organisation Type

Patient organisation/association

Country Of Registered Address

Austria